Clinical trials: Methylphenidate
ADHD, Stimulant-Induced Euphoria
Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist
The purpose of this study is to a) assess the efficacy of naltrexone in preventing stimulant-induced euphoria in adults with ADHD, b) assess whether naltrexone will interfere with the clinical efficacy of stimulants in treating…
- Trial name
- NCT01673594
- Testing
- SODAS MPH, Naltrexone
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Massachusetts General Hospital
Attention Deficit Disorder With Hyperactivity
Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to determine the effectiveness of behavioral treatment, drug treatment, and combined treatment for children with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT00050622
- Testing
- Methylphenidate 0.15 mg/kg, Low-Intensity BMOD, Methylphenidate 0.3 mg/kg
- Where
- 2 sites in United States
- Volunteers
- 154 people
- Sponsor
- Florida International University
Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
RATIONALE: Methylphenidate may help relieve fatigue caused by cancer. It is not yet known whether methylphenidate is more effective than a placebo in relieving fatigue and improving quality of life in patients with cancer.
- Trial name
- NCT00376675
- Testing
- methylphenidate hydrochloride
- Where
- 238 sites in United States
- Volunteers
- 148 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Healthy
A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults
This is a double-blind, randomized, placebo-controlled, five-period crossover study to examine the likability of a repeated administration of immediate release methylphenidate hydrochloride (IR-MPH 40 mg) and OROS®-MPH (CONCERTA®…
- Trial name
- NCT00302458
- Testing
- OROS-Methylphenidate, Immediate Release Methylphenidate
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Alzheimer's Disease, Apathy
Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study
The purpose of the study is to determine the efficacy of methylphenidate over placebo in treating apathy in patients with Alzheimer's dementia.
- Conditions
- Alzheimer's Disease, Apathy, Dementia
- Trial name
- NCT00495820
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- VA Office of Research and Development
Attention-Deficit/Hyperactivity Disorder (ADHD)
A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)
The purpose of this study is to investigate the safety and efficacy of an investigational treatment for Attention Deficit Hyperactivity Disorder (ADHD) when compared to placebo.
- Trial name
- NCT00475735
- Testing
- MK0249, Concerta (methylphenidate)
- Volunteers
- 72 people
- Sponsor
- Merck Sharp & Dohme LLC
Attention Deficit Disorder With Hyperactivity
Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior.
The primary purpose of this thirteen-week, open-label study is to test the hypothesis that quetiapine in combination with Oros methylphenidate will reduce aggressive symptoms in children and adolescents who have shown inadequate…
- Trial name
- NCT00550147
- Testing
- Oros Methylphenidate, quetiapine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Indiana University
Depression, Palliative Care
Methylphenidate for Depressed Cancer Patients Receiving Palliative Care
The purpose of this study is to determine whether methylphenidate is an effective treatment for depression and to document the safety and tolerability of methylphenidate in combination with an Selective Serotonin Reuptake…
- Conditions
- Depression, Palliative Care, Cancer, Mental Disorder
- Trial name
- NCT00129467
- Testing
- Methylphenidate, Selective Serotonin Uptake Inhibitor (SSRI)
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- US Department of Veterans Affairs
Parkinson's Disease, Gait Impairment
Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease
The purpose of this research study is to examine whether Methylphenidate (MPD) can result in improvement of gait (walking) in a population of Parkinson's Disease (PD) patients whose main disability is freezing of gait.
- Trial name
- NCT00526630
- Testing
- Methylphenidate (MPD)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Cincinnati
ALL, Childhood, Leukemia, Lymphoblastic
Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors
While neurocognitive impairments in attention, memory and executive functioning are commonly reported sequelae of childhood leukemia and brain tumors, studies have only recently begun to examine the treatment of attention…
- Conditions
- ALL, Childhood, Leukemia, Lymphoblastic, Leukemia, Lymphoblastic, Acute, Leukemia, Lymphoblastic, Acute, L1
- Trial name
- NCT01100658
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Minnesota
Attention Deficit Hyperactivity Disorder
Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD
This study will look at the effectiveness of Methylphenidate Transdermal System (MTS) in treating adult ADHD. MTS has received FDA approval for childhood ADHD but this is the first trial for adult ADHD.
- Trial name
- NCT00506285
- Testing
- Methylphenidate Transdermal System (MTS)
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- University of Utah
Attention Deficit Hyperactivity Disorder
Gene-environment Interactions and Brain Functional Connectivity in Attention Deficit Hyperactivity Disorder
The aims of the current study are to examine gene-environment interactions associated with norepinephrine (NE) system genes (ADRA2A, SLC6A2) in ADHD, and to evaluate whether genetic changes in norepinephrine pathway are…
- Trial name
- NCT01912352
- Testing
- Methylphenidate
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Seoul National University
Attention Deficit/Hyperactivity Disorder
Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder
This study will evaluate the long-term safety of methylphenidate hydrochloride extended release in adults with attention deficit/hyperactivity disorder
- Trial name
- NCT01338818
- Testing
- Ritalin LA (methylphenidate hydrochloride extended release)
- Where
- 48 sites in United States, Belgium and 4 more
- Volunteers
- 299 people
- Sponsor
- Novartis Pharmaceuticals
Attention Deficit/Hyperactivity Disorder
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
This study will evaluate efficacy and safety of methylphenidate hydrochloride extended release compared to placebo in adult patients with childhood-onset attention deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT01259492
- Testing
- Ritalin LA 20 mg, Ritalin LA 30 mg
- Where
- 68 sites in United States, Belgium and 7 more
- Volunteers
- 725 people
- Sponsor
- Novartis Pharmaceuticals
Hoarding Disorder
Enhancing Attention in Adults With Compulsive Hoarding
Available data suggest that compulsive hoarders have cognitive deficits, particularly with sustaining attention that might contribute their hoarding symptoms.
- Trial name
- NCT01100268
- Testing
- Methylphenidate ER
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- New York State Psychiatric Institute
Attention Deficit Hyperactivity Disorder (ADHD)
A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants
The purpose of this long term post-marketing study is to evaluate the effectiveness and safety of osmotic release oral system methylphenidate hydrochloride (OROS-MPH) in participants with Attention Deficit Hyperactivity Disorder…
- Trial name
- NCT01933880
- Testing
- Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH), No intervention
- Where
- 6 sites in China
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Attention Deficit Hyperactivity Disorder
A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder
The primary purpose of your child's participation in this study is to determine whether LY2216684 can help pediatric patients with attention-deficit/hyperactivity disorder (ADHD); and assess the safety of LY2216684 and any side…
- Trial name
- NCT00922636
- Testing
- LY2216684, Methylphenidate
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 340 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
The objective of this study was to establish that an optimal dose of Quillivant XR oral suspension would result in a significant reduction in signs and symptoms of ADHD compared to placebo treatment in pediatric patients ages…
- Trial name
- NCT00904670
- Testing
- Quillivant Oral Suspension XR
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Pfizer
Attention Deficit Hyperactivity Disorder
Lab School Day Study for CONCERTA of Older Children With ADHD
The purpose of this trial is to determine if the study medication, CONCERTA (methylphenidate HCl), is safe and effective in improving academic performance and behavior in children with attention deficit hyperactivity disorder…
- Trial name
- NCT00799409
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Attention Deficit/ Hyperactivity Disorder
A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder
The purpose of this study is to evaluate the efficacy of 2 fixed dosages of Prolonged Release (PR) OROS methylphenidate (54 and 72 mg/day) compared with placebo in adult patients with attention deficit/hyperactivity disorder…
- Trial name
- NCT00714688
- Testing
- prolonged release (PR) OROS methylphenidate 54 mg, prolonged release (PR) OROS methylphenidate 72 mg
- Where
- 42 sites in Belgium, Denmark and 9 more
- Volunteers
- 279 people
- Sponsor
- Janssen-Cilag International NV